Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% Return-on-Tangible-Asset is 0.03% as of Jun. 2026. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, MediPharm Labs ranks worse than 77.36% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. MediPharm Labs's annualizedNet Income for the quarter that ended in Jun. 2026 was €0.01 Mil. MediPharm Labs's average total tangible assets for the quarter that ended in Jun. 2026 was €27.59 Mil. Therefore, MediPharm Labs's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 0.03%.
The historical rank and industry rank for MediPharm Labs's Return-on-Tangible-Asset or its related term are showing as below:
STU:MLZ'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -52.11 Med: -29.2 Max: 1.94
Current: -10.91
During the past 9 years, MediPharm Labs's highest Return-on-Tangible-Asset was 1.94%. The lowest was -52.11%. And the median was -29.20%.
STU:MLZ's Return-on-Tangible-Asset is ranked worse than 77.36% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.89
vs STU:MLZ: -10.91
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
MediPharm Labs Return-on-Tangible-Asset Related Terms
MediPharm Labs Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MLZ vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.03% mean?
MediPharm Labs (STU:MLZ) has a Return-on-Tangible-Asset of 0.03% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on MediPharm Labs and its competitors. According to the industry distribution chart, MediPharm Labs ranks #779 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is MediPharm Labs' Return-on-Tangible-Asset too high?
MediPharm Labs' current Return-on-Tangible-Asset is 0.03%. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.89. MediPharm Labs' value of 0.03% is 99% below this industry median. Based on the distribution chart, MediPharm Labs ranks #779 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MediPharm Labs' Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #779 out of 1007 companies for Return-on-Tangible-Asset. This places MediPharm Labs in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.89. MediPharm Labs' value of 0.03% is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.89, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current Return-on-Tangible-Asset of 0.03% is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current Return-on-Tangible-Asset is 0.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current Return-on-Tangible-Asset is 0.03% and 99% below the Drug Manufacturers industry median of 2.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current Return-on-Tangible-Asset is 0.03% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
